Jerusalem, Israel: The administration of oral THC mitigates symptoms of post-traumatic stress syndrome (PTSD), according to clinical trial data published online ahead of print in the journal Clinical Drug Investigation.
Investigators at the Hebrew University Medical Center in Jerusalem assessed the safety and efficacy of oral THC as an adjunct treatment in ten subjects with chronic PTSD.
Researchers reported, "The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms."
They concluded, "Orally absorbable delta-9-THC was safe and well tolerated by patients with chronic PTSD."
Separate clinical trial data has previously reported that the administration of nabilone, a synthetic endocannabinoid agonist, can reduce the severity and frequency of nightmares in patients with PTSD.
In 2013, researchers at the New York University School of Medicine published findings indicating that PTSD subjects experience a decrease in their natural production of anandamide, an endogenous cannabinoid neurotransmitter. They hypothesized that an increase in the body's production of cannabinoids would likely restore subjects' natural brain chemistry and psychological balance. They affirmed, "[Our] findings substantiate, at least in part, emerging evidence that ... plant-derived cannabinoids such as marijuana may possess some benefits in individuals with PTSD by helping relieve haunting nightmares and other symptoms of PTSD."
For more information, please contact Paul Armentano, NORML Deputy Director, at: email@example.com. Full text of the study, "Preliminary, open-label, pilot study of add-on oral delta-9-tetrahydrocannabinol in chronic post-traumatic stress disorder," will appear in Clinical Drug Investigation.